Ardelyx Inc (ARDX NASDAQ) stock market data APIs
$5.445
0.29(5.6%)
as of March 21, 2025
Ardelyx Inc Financial Data Overview
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Prev. Close
5.1545
Open
5.445
High
5.5251
Low
4.9702
52 wk Range
4.32-9.33
Market Cap
1 306 M
Shares Outstanding
238 M
Revenue
334 M
EPS
0.02
Beta
0.869
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Ardelyx Inc data using free add-ons & libraries
Get Ardelyx Inc Fundamental Data
Ardelyx Inc Fundamental data includes:
- Net Revenue: 334 M
- EBITDA: -25 887 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-20
- EPS/Forecast: -0.0007
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ardelyx Inc News
New
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
WALTHAM, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
Ardelyx, Inc. Award established to recognize leaders in the field of chronic kidney disease advocacy WALTHAM, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceuti...
High Growth Tech Stocks In The US With Promising Potential
Over the last 7 days, the United States market has experienced a 1.7% drop, yet it remains up by 12% over the past year with earnings forecasted to grow by 14% annually. In this context, identifying h...
Ardelyx Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Ardelyx (NASDAQ:ARDX) Full Year 2024 Results Key Financial Results Revenue: US$333.6m (up 168% from FY 2023). Net loss: US$39.1m (loss narrowed by 41% from FY 2023). US$0.17 loss per share (improved...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
